New

Acute Myeloid Leukemia Market

2021

Acute Myeloid Leukemia Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Drug Class (Tyrosine Kinase Inhibitors, Hedgehog Pathway Inhibitors, Topoisomerase 2 Inhibitors, and Others); End Use (Hospital, Clinic, and Others), and Geography

| Report Code: TIPRE00023422 | No. of Pages: 150 | Category: Pharmaceuticals | Status: Upcoming

Market Insights

Acute Myeloid Leukemia Market 2028 By Drug Class, End Use, and Geography | The Insight Partners

Covid
Assesing the covid-19 impact?
Get the Latest COVID-19 Analysis on this market
Request Now
Happy to join you in your fight against the COVID-19 economic pandemic!
MARKET OVERVIEW

Acute Myeloid Leukemia is a cancer of myeloid blood cells, causing extreme and rapid growth of abnormal white blood cells of the bone marrow. The rapid build-up of abnormal white blood cells causes interference in the production of normal blood cells. Acute Myeloid Leukemia has a propensity to increase towards age. Replacement of bone marrow with cancer cells causes a drop in blood constituents such as red blood cells, platelets, white blood cells, etc. This causes symptoms such as fatigue, breathlessness, easy bruising, and bleeding.

MARKET SCOPE

The "Global Acute Myeloid Leukemia Market Analysis to 2028" is a specialized and in-depth study of the pharmaceutical industry with a special focus on the global market trend analysis. The report aims to provide an overview of the Acute myeloid leukemia market with detailed market segmentation by type, end use, and geography. The report provides key statistics on the market status of the leading Acute myeloid leukemia market players and offers key trends and opportunities in the market.

MARKET SEGMENTATION

  •  Based on drug class, the global Acute myeloid leukemia market is segmented into tyrosine kinase inhibitors, hedgehog pathway inhibitors, topoisomerase 2 inhibitors, others.
  •  On the basis of end use, the market is segmented into hospital, clinic, others.

MARKET DYNAMICS
Drivers

  •  Rise in the incidences of prevalence of Acute Myeloid Leukemia.
  •  Advancements in pharmacology and molecular biology to promote drug development.
  •  Increasing R&D investment.

Restraints

  •  The complications related to chemotherapy is the major restraining factor for this market.

REGIONAL FRAMEWORK

The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides an overview and forecast of the global market based on various segments. It also provides market size and forecast estimates from the year 2019 to 2028 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), the Middle East and Africa (MEA), and South America. The Acute myeloid leukemia market by each region is later sub-segmented by respective countries and segments. The report covers the analysis and forecast of 18 countries globally along with the current trend and opportunities prevailing in the region.

The report analyzes factors affecting the market from both demand and supply side and further evaluates market dynamics affecting the marketduring the forecast period i.e., drivers, restraints, opportunities, and future trend. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA, and South America after evaluating political, economic, social and technological factors affecting the Acute myeloid leukemia market in these regions.

IMPACT OF COVID-19 ON ACUTE MYELOID LEUKEMIA MARKET

COVID-19 first began in Wuhan (China) during December 2019 and since then it has spread at a fast pace across the globe. The US, India, Brazil, Russia, France, the UK, Turkey, Italy, and Spain are some of the worst affected countries in terms confirmed cases and reported deaths. The COVID-19 has been affecting economies and industries in various countries due to lockdowns, travel bans, and business shutdowns. Shutdown of various plants and factories has affected the global supply chains and negatively impacted the manufacturing, delivery schedules, and sales of products in global market. Few companies have already announced possible delays in product deliveries and slump in future sales of their products. In addition to this, the global travel bans imposed by countries in Europe, Asia-Pacific, and North America are affecting the business collaborations and partnerships opportunities.



Get more information on this report :

MARKET PLAYERS


The report covers key developments in the Acute myeloid leukemia market as organic and inorganic growth strategies. Various companies are focusing on organic growth strategies such as product launches, product approvals and others such as patents and events. Inorganic growth strategies activities witnessed in the marketwere acquisitions, and partnership & collaborations. These activities have paved way for the expansion of business and customer base of market players. The market payers from Acute myeloid leukemia market are anticipated to lucrative growth opportunities in the future with the rising demand for Acute myeloid leukemia in the global market.

The report also includes the profiles of key companies along with their SWOT analysis and market strategies in the Acute myeloid leukemia market. In addition, the report focuses on leading industry players with information such as company profiles, components, and services offered, financial information of the last 3 years, the key development in the past five years.

  •  Johnson & Johnson Private Limited
  •  Pfizer Inc
  •  Abbott
  •  AstraZeneca
  •  Bayer
  •  Celgene Corporation
  •  Ambit Biosciences Corporation
  •  Cyclacel Pharmaceuticals Inc
  •  Novartis AG
  •  Sanofi

The Insight Partner's dediAcute myeloid leukemiaed research and analysis team consist of experienced professionals with advanced statistical expertise and offer various customization options in the existing study.


Get more information on this report :

TABLE OF CONTENTS

1. INTRODUCTION
1.1. SCOPE OF THE STUDY
1.2. THE INSIGHT PARTNERS RESEARCH REPORT GUIDANCE
1.3. MARKET SEGMENTATION
1.3.1 Acute Myeloid Leukemia Market - By Drug Class
1.3.2 Acute Myeloid Leukemia Market - By End Use
1.3.3 Acute Myeloid Leukemia Market - By Region
1.3.3.1 By Country
2. KEY TAKEAWAYS
3. RESEARCH METHODOLOGY
4. ACUTE MYELOID LEUKEMIA MARKET LANDSCAPE
4.1. OVERVIEW
4.2. PEST ANALYSIS
4.2.1 North America - Pest Analysis
4.2.2 Europe - Pest Analysis
4.2.3 Asia-Pacific - Pest Analysis
4.2.4 Middle East and Africa - Pest Analysis
4.2.5 South and Central America - Pest Analysis
4.3. EXPERT OPINIONS
5. ACUTE MYELOID LEUKEMIA MARKET - KEY MARKET DYNAMICS
5.1. KEY MARKET DRIVERS
5.2. KEY MARKET RESTRAINTS
5.3. KEY MARKET OPPORTUNITIES
5.4. FUTURE TRENDS
5.5. IMPACT ANALYSIS OF DRIVERS AND RESTRAINTS
6. ACUTE MYELOID LEUKEMIA MARKET - GLOBAL MARKET ANALYSIS
6.1. ACUTE MYELOID LEUKEMIA - GLOBAL MARKET OVERVIEW
6.2. ACUTE MYELOID LEUKEMIA - GLOBAL MARKET AND FORECAST TO 2028
6.3. MARKET POSITIONING
7. ACUTE MYELOID LEUKEMIA MARKET - REVENUE AND FORECASTS TO 2028 - DRUG CLASS
7.1. OVERVIEW
7.2. DRUG CLASS MARKET FORECASTS AND ANALYSIS
7.3. TYROSINE KINASE INHIBITORS
7.3.1. Overview
7.3.2. Tyrosine Kinase Inhibitors Market Forecast and Analysis
7.4. HEDGEHOG PATHWAY INHIBITORS
7.4.1. Overview
7.4.2. Hedgehog Pathway Inhibitors Market Forecast and Analysis
7.5. TOPOISOMERASE 2 INHIBITORS
7.5.1. Overview
7.5.2. Topoisomerase 2 Inhibitors Market Forecast and Analysis
7.6. OTHERS
7.6.1. Overview
7.6.2. Others Market Forecast and Analysis
8. ACUTE MYELOID LEUKEMIA MARKET - REVENUE AND FORECASTS TO 2028 - END USE
8.1. OVERVIEW
8.2. END USE MARKET FORECASTS AND ANALYSIS
8.3. HOSPITAL
8.3.1. Overview
8.3.2. Hospital Market Forecast and Analysis
8.4. CLINIC
8.4.1. Overview
8.4.2. Clinic Market Forecast and Analysis
8.5. OTHERS
8.5.1. Overview
8.5.2. Others Market Forecast and Analysis
9. ACUTE MYELOID LEUKEMIA MARKET REVENUE AND FORECASTS TO 2028 - GEOGRAPHICAL ANALYSIS
9.1. NORTH AMERICA
9.1.1 North America Acute Myeloid Leukemia Market Overview
9.1.2 North America Acute Myeloid Leukemia Market Forecasts and Analysis
9.1.3 North America Acute Myeloid Leukemia Market Forecasts and Analysis - By Drug Class
9.1.4 North America Acute Myeloid Leukemia Market Forecasts and Analysis - By End Use
9.1.5 North America Acute Myeloid Leukemia Market Forecasts and Analysis - By Countries
9.1.5.1 United States Acute Myeloid Leukemia Market
9.1.5.1.1 United States Acute Myeloid Leukemia Market by Drug Class
9.1.5.1.2 United States Acute Myeloid Leukemia Market by End Use
9.1.5.2 Canada Acute Myeloid Leukemia Market
9.1.5.2.1 Canada Acute Myeloid Leukemia Market by Drug Class
9.1.5.2.2 Canada Acute Myeloid Leukemia Market by End Use
9.1.5.3 Mexico Acute Myeloid Leukemia Market
9.1.5.3.1 Mexico Acute Myeloid Leukemia Market by Drug Class
9.1.5.3.2 Mexico Acute Myeloid Leukemia Market by End Use
9.2. EUROPE
9.2.1 Europe Acute Myeloid Leukemia Market Overview
9.2.2 Europe Acute Myeloid Leukemia Market Forecasts and Analysis
9.2.3 Europe Acute Myeloid Leukemia Market Forecasts and Analysis - By Drug Class
9.2.4 Europe Acute Myeloid Leukemia Market Forecasts and Analysis - By End Use
9.2.5 Europe Acute Myeloid Leukemia Market Forecasts and Analysis - By Countries
9.2.5.1 Germany Acute Myeloid Leukemia Market
9.2.5.1.1 Germany Acute Myeloid Leukemia Market by Drug Class
9.2.5.1.2 Germany Acute Myeloid Leukemia Market by End Use
9.2.5.2 France Acute Myeloid Leukemia Market
9.2.5.2.1 France Acute Myeloid Leukemia Market by Drug Class
9.2.5.2.2 France Acute Myeloid Leukemia Market by End Use
9.2.5.3 Italy Acute Myeloid Leukemia Market
9.2.5.3.1 Italy Acute Myeloid Leukemia Market by Drug Class
9.2.5.3.2 Italy Acute Myeloid Leukemia Market by End Use
9.2.5.4 Spain Acute Myeloid Leukemia Market
9.2.5.4.1 Spain Acute Myeloid Leukemia Market by Drug Class
9.2.5.4.2 Spain Acute Myeloid Leukemia Market by End Use
9.2.5.5 United Kingdom Acute Myeloid Leukemia Market
9.2.5.5.1 United Kingdom Acute Myeloid Leukemia Market by Drug Class
9.2.5.5.2 United Kingdom Acute Myeloid Leukemia Market by End Use
9.2.5.6 Rest of Europe Acute Myeloid Leukemia Market
9.2.5.6.1 Rest of Europe Acute Myeloid Leukemia Market by Drug Class
9.2.5.6.2 Rest of Europe Acute Myeloid Leukemia Market by End Use
9.3. ASIA-PACIFIC
9.3.1 Asia-Pacific Acute Myeloid Leukemia Market Overview
9.3.2 Asia-Pacific Acute Myeloid Leukemia Market Forecasts and Analysis
9.3.3 Asia-Pacific Acute Myeloid Leukemia Market Forecasts and Analysis - By Drug Class
9.3.4 Asia-Pacific Acute Myeloid Leukemia Market Forecasts and Analysis - By End Use
9.3.5 Asia-Pacific Acute Myeloid Leukemia Market Forecasts and Analysis - By Countries
9.3.5.1 Australia Acute Myeloid Leukemia Market
9.3.5.1.1 Australia Acute Myeloid Leukemia Market by Drug Class
9.3.5.1.2 Australia Acute Myeloid Leukemia Market by End Use
9.3.5.2 China Acute Myeloid Leukemia Market
9.3.5.2.1 China Acute Myeloid Leukemia Market by Drug Class
9.3.5.2.2 China Acute Myeloid Leukemia Market by End Use
9.3.5.3 India Acute Myeloid Leukemia Market
9.3.5.3.1 India Acute Myeloid Leukemia Market by Drug Class
9.3.5.3.2 India Acute Myeloid Leukemia Market by End Use
9.3.5.4 Japan Acute Myeloid Leukemia Market
9.3.5.4.1 Japan Acute Myeloid Leukemia Market by Drug Class
9.3.5.4.2 Japan Acute Myeloid Leukemia Market by End Use
9.3.5.5 South Korea Acute Myeloid Leukemia Market
9.3.5.5.1 South Korea Acute Myeloid Leukemia Market by Drug Class
9.3.5.5.2 South Korea Acute Myeloid Leukemia Market by End Use
9.3.5.6 Rest of Asia-Pacific Acute Myeloid Leukemia Market
9.3.5.6.1 Rest of Asia-Pacific Acute Myeloid Leukemia Market by Drug Class
9.3.5.6.2 Rest of Asia-Pacific Acute Myeloid Leukemia Market by End Use
9.4. MIDDLE EAST AND AFRICA
9.4.1 Middle East and Africa Acute Myeloid Leukemia Market Overview
9.4.2 Middle East and Africa Acute Myeloid Leukemia Market Forecasts and Analysis
9.4.3 Middle East and Africa Acute Myeloid Leukemia Market Forecasts and Analysis - By Drug Class
9.4.4 Middle East and Africa Acute Myeloid Leukemia Market Forecasts and Analysis - By End Use
9.4.5 Middle East and Africa Acute Myeloid Leukemia Market Forecasts and Analysis - By Countries
9.4.5.1 South Africa Acute Myeloid Leukemia Market
9.4.5.1.1 South Africa Acute Myeloid Leukemia Market by Drug Class
9.4.5.1.2 South Africa Acute Myeloid Leukemia Market by End Use
9.4.5.2 Saudi Arabia Acute Myeloid Leukemia Market
9.4.5.2.1 Saudi Arabia Acute Myeloid Leukemia Market by Drug Class
9.4.5.2.2 Saudi Arabia Acute Myeloid Leukemia Market by End Use
9.4.5.3 U.A.E Acute Myeloid Leukemia Market
9.4.5.3.1 U.A.E Acute Myeloid Leukemia Market by Drug Class
9.4.5.3.2 U.A.E Acute Myeloid Leukemia Market by End Use
9.4.5.4 Rest of Middle East and Africa Acute Myeloid Leukemia Market
9.4.5.4.1 Rest of Middle East and Africa Acute Myeloid Leukemia Market by Drug Class
9.4.5.4.2 Rest of Middle East and Africa Acute Myeloid Leukemia Market by End Use
9.5. SOUTH AND CENTRAL AMERICA
9.5.1 South and Central America Acute Myeloid Leukemia Market Overview
9.5.2 South and Central America Acute Myeloid Leukemia Market Forecasts and Analysis
9.5.3 South and Central America Acute Myeloid Leukemia Market Forecasts and Analysis - By Drug Class
9.5.4 South and Central America Acute Myeloid Leukemia Market Forecasts and Analysis - By End Use
9.5.5 South and Central America Acute Myeloid Leukemia Market Forecasts and Analysis - By Countries
9.5.5.1 Brazil Acute Myeloid Leukemia Market
9.5.5.1.1 Brazil Acute Myeloid Leukemia Market by Drug Class
9.5.5.1.2 Brazil Acute Myeloid Leukemia Market by End Use
9.5.5.2 Argentina Acute Myeloid Leukemia Market
9.5.5.2.1 Argentina Acute Myeloid Leukemia Market by Drug Class
9.5.5.2.2 Argentina Acute Myeloid Leukemia Market by End Use
9.5.5.3 Rest of South and Central America Acute Myeloid Leukemia Market
9.5.5.3.1 Rest of South and Central America Acute Myeloid Leukemia Market by Drug Class
9.5.5.3.2 Rest of South and Central America Acute Myeloid Leukemia Market by End Use
10. IMPACT OF COVID-19 PANDEMIC ON GLOBAL ACUTE MYELOID LEUKEMIA MARKET
10.1 North America
10.2 Europe
10.3 Asia-Pacific
10.4 Middle East and Africa
10.5 South and Central America
11. INDUSTRY LANDSCAPE
11.1. MERGERS AND ACQUISITIONS
11.2. AGREEMENTS, COLLABORATIONS AND JOIN VENTURES
11.3. NEW PRODUCT LAUNCHES
11.4. EXPANSIONS AND OTHER STRATEGIC DEVELOPMENTS
12. ACUTE MYELOID LEUKEMIA MARKET, KEY COMPANY PROFILES
12.1. JOHNSON AND JOHNSON PRIVATE LIMITED
12.1.1. Key Facts
12.1.2. Business Description
12.1.3. Products and Services
12.1.4. Financial Overview
12.1.5. SWOT Analysis
12.1.6. Key Developments
12.2. PFIZER INC
12.2.1. Key Facts
12.2.2. Business Description
12.2.3. Products and Services
12.2.4. Financial Overview
12.2.5. SWOT Analysis
12.2.6. Key Developments
12.3. ABBOTT
12.3.1. Key Facts
12.3.2. Business Description
12.3.3. Products and Services
12.3.4. Financial Overview
12.3.5. SWOT Analysis
12.3.6. Key Developments
12.4. ASTRAZENECA
12.4.1. Key Facts
12.4.2. Business Description
12.4.3. Products and Services
12.4.4. Financial Overview
12.4.5. SWOT Analysis
12.4.6. Key Developments
12.5. BAYER
12.5.1. Key Facts
12.5.2. Business Description
12.5.3. Products and Services
12.5.4. Financial Overview
12.5.5. SWOT Analysis
12.5.6. Key Developments
12.6. CELGENE CORPORATION
12.6.1. Key Facts
12.6.2. Business Description
12.6.3. Products and Services
12.6.4. Financial Overview
12.6.5. SWOT Analysis
12.6.6. Key Developments
12.7. AMBIT BIOSCIENCES CORPORATION
12.7.1. Key Facts
12.7.2. Business Description
12.7.3. Products and Services
12.7.4. Financial Overview
12.7.5. SWOT Analysis
12.7.6. Key Developments
12.8. CYCLACEL PHARMACEUTICALS INC
12.8.1. Key Facts
12.8.2. Business Description
12.8.3. Products and Services
12.8.4. Financial Overview
12.8.5. SWOT Analysis
12.8.6. Key Developments
12.9. NOVARTIS AG
12.9.1. Key Facts
12.9.2. Business Description
12.9.3. Products and Services
12.9.4. Financial Overview
12.9.5. SWOT Analysis
12.9.6. Key Developments
12.10. SANOFI
12.10.1. Key Facts
12.10.2. Business Description
12.10.3. Products and Services
12.10.4. Financial Overview
12.10.5. SWOT Analysis
12.10.6. Key Developments
13. APPENDIX
13.1. ABOUT THE INSIGHT PARTNERS
13.2. GLOSSARY OF TERMS
The List of Companies

1. Johnson & Johnson Private Limited
2. Pfizer Inc
3. Abbott
4. AstraZeneca
5. Bayer
6. Celgene Corporation
7. Ambit Biosciences Corporation
8. Cyclacel Pharmaceuticals Inc
9. Novartis AG
10. Sanofi
TIPRE00023422
Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.

Pricing

Free

20%

customization on Pre-Booking
Request for Sample
Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.